Summary
This pilot study was carried out on 23 gynaecological patients suffering from salpingitis, salpingitis and pelviperitonitis, Douglas' abscess, and vaginal stump abscess. 21 courses were evaluable for clinical efficacy. The diagnoses had been established mainly by pelviscopy and by clinical gynaecological examinations. The dosage was 2 × 500 mg ciprofloxacin orally every 12 h for 7.6 (5–11) days. Cervical smears collected before therapy revealed the most common pathogens to beEscherichia coli and staphylococci, followed byProteus mirabilis and streptococci. Clinically ciprofloxacin produced a complete cure in 16 patients (76%), and a clear improvement in four patients (19%). One patient left hospital before completing the therapy. Laboratory tests did not reveal any pathological findings, and ophthalmological examinations (fundoscopy, visus, colour perception) on 16 patients, before and after treatment, likewise did not show any changes. In one patient, therapy had to be discontinued after three days because of pruritic exanthema and vertigo. A second patient complained of strong pain behind the eyes and headache. In both patients these symptoms disappeared completely on discontinuation of treatment. The study showed clinical efficacy of orally administered ciprofloxacin in pelvic inflammatory disease.
Zusammenfassung
In diese Pilotstudie wurden 23 gynäkologische Patientinnen, die an Salpingitis, Salpingitis mit Pelviperitonitis, Douglas-Abszeß und Vaginalstumpfabszeß litten, einbezogen. 21 Behandlungsverläufe waren für die Beurteilung der klinischen Wirksamkeit auswertbar. Die Diagnose wurde hauptsächlich durch Pelviskopie und klinisch-gynäkologische Untersuchungen gestützt. 2× 500 mg Ciprofloxacin wurde alle 12 Stunden verabreicht, die Therapiedauer betrug im Mittel 7,6 (5–11) Tage. Vor Beginn der antibiotischen Therapie wurden folgende Krankheitserreger aus dem Vaginalabstrich isoliert:Escherichia coli, Staphylokokken,Proteus mirabilis und Streptokokken. Die Ciprofloxacin-Therapie führte bei 16 Patientinnen (76%) zur vollständigen Heilung, bei weiteren vier Patientinnen (19%) zu einer deutlichen klinischen Besserung. Eine Patientin verließ die Klinik, bevor die geplante Therapie beendet werden konnte. Laboruntersuchungen erbrachten keinen Hinweis auf Ciprofloxacin-bedingte Nebenwirkungen. Desgleichen waren umfangreiche ophthalmologische Untersuchungen (Fundoskopie, Visus, Farbsehen), die bei 16 Patientinnen vor und nach der Therapie durchgeführt wurden, negativ. Bei einer Patientin mußte Ciprofloxacin wegen eines juckenden Exanthems und Schwindel nach drei Tagen abgesetzt werden. Eine weitere Patientin klagte über starke Schmerzen hinter den Augen sowie über Kopfschmerzen. Bei beiden Patientinnen war die Nebenwirkung nach Absetzen voll reversibel. In dieser Studie zeigte oral verabreichtes Ciprofloxacin klinische Wirksamkeit bei Infektionen im Bereich des kleinen Beckens.
Similar content being viewed by others
Literature
Emmons, J., Courter, P. Towards control of chlamydial infections. Nurse Pract. 10 (1985). 15–16; 21–22.
Washington, A. E., Arno, P. S., Brooks, M. A. The economic cost of pelvic inflammatory disease. J. Am. Med. Assoc. 255 (1986) 1735–1738.
Handsfild, H. H. Recent development in gonorrhea and pelvic inflammatory disease. J. Med. 14 (1983) 281–305.
Ledger, W. J. The next ten years in the treatment of pelvic infections. Am. J. Med. 78 (6B) (1985) 194–203.
Jones, R. B., Ardery, B. R., Hui, S. L., Cleary, R. E. Correlation between serum antichlamydial antibodies and tubal factor as a cause of infertility. Fertil. Steril. 38 (1982) 553–558.
Eschenbach, D. A. Acute pelvic inflammatory disease. Urol. Clin. North. Am. 11 (1984) 65–81.
Gjonnaess, H., Dalaker, K., Anestad, G., Mårdh, P. A., Kvile, G. Pelvic inflammatory disease: etiologic studies with emphasis on chlamydial infection. Obstet. Gynecol. 59 (1982) 550–555.
Westergaard, L., Philipsen, T., Scheibel, J. Significance of cervicalChlamydia trachomatis infection in postabortal pelvic inflammatory disease. Obstet. Gynecol. 60 (1982) 322–325.
Eschenbach, D. A., Buchanan, T. M., Pollack, H. M. Polymicrobial etiology of acute pelvic inflammatory disease. N. Engl. J. Med. 293 (1975) 166–171.
Moller, B. R., Mårdh, P. A., Ahrons, S., Nüssler, E. Infection withChlamydia trachomatis, Mycoplasma hominis andNeisseria gonorrhoeae in patients with acute pelvic inflammatory disease. Sex. Transm. Dis. 8 (1981) 198–202.
Taylor-Robinson, D. Ureaplasmas as a cause of disease in man and animals: fact or fancy? Isr. J. Med. Sci. 20 (1984) 843–847.
Bauernfeind, A., Petermüller, C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur. J. Clin. Microbiol. 2 (1983) 111–115.
Wise, R., Andrews, J. M., Edwards, L. S. In vitro activity of BAY o 9867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob. Agents Chemother. 23 (1983) 559–564.
Blenk, H., Blenk, B.: Susceptibility of genital mycoplasma- and chlamydia-strains against ciprofloxacin. 4th Mediterranean Congress of Chemotherapy, Rhodes, 1984, Abstract no. 309.
Machka, K. In vitro activity of ciprofloxacin and norfloxacin againstGardnerella vaginalis. Eur. J. Clin. Microbiol. 3 (1984) 374.
Meier-Ewert, H., Weil, G., Millot, G. In vitro activity of ciprofloxacin against clinical isolates ofChlamydia trachomatis. Eur. J. Clin. Microbiol. 3 (1984) 372.
Ridgway, G. L., Muntaz, G., Gabriel, F. G., Ariel, J. D. The activity of ciprofloxacin and other 4-quinolones againstChlamydia trachomatis and Mycoplasmain vitro. Eur. J. Clin. Microbiol. 3 (1984) 344–346.
Eschenbach, D. A. Acute pelvic inflammatory disease. Etiology, risk factors and pathogenesis. Clin. Obstet. Gynecol. 19 (1976) 147–169.
Gilbert, G. L. Acute salpingitis. Diagnostic and therapeutic dilemmas. Aust. Fam. Physician 13 (1984) 665–672.
Rafferty, E. G. Chlamydial infections in women. JOGN Nurs. 10 (1981) 299–301.
Bergan, T., Dalhoff, A., Engeset, A., Olszewski, Thorsteinsson, S. B.: A review of pharmacokinetics and tissue penetration of ciprofloxacin. Proceedings of a Workshop held at the 14th International Congress of Chemotherapy, Kyoto, 1985, pp. 23–36.
Burgaleta, C., Moreno, T., Loza, E.: Killing of intraphagocyticEscherichia coli by ciprofloxacin. 25th ICAAC, Minneapolis, 1985, Abstract no. 399.
Easmon, C. S. F., Crane, J. P. Uptake of ciprofloxacin by human neutrophils. J. Antimicrob. Chemother. 16 (1985) 67–73.
Easmon, C. S. F., Crane, J. P. Uptake of ciprofloxacin by macrophages. J. Clin. Pathol. 38 (1985) 442–444.
Traub, W. H. Intraphagocytic bacterial activity of bacterial DNA gyrase inhibitors againstSerratia marcescens. Chemotherapy 30 (1984) 379–386.
Goormans, E., Dalhoff, A., Kazzas, B., Branolte, J. Penetration of ciprofloxacin into gynecological tissues following oral and intravenous administration. Chemotherapy 32 (1986) 7–17.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hägele, D., Chyský, V. Is pelvic inflammatory disease an indication for treatment with ciprofloxacin?. Infection 16 (Suppl 1), S48–S50 (1988). https://doi.org/10.1007/BF01650507
Issue Date:
DOI: https://doi.org/10.1007/BF01650507